following an abbreviated submission:
cabozantinib (Cabometyx®) is accepted for use within NHSScotland.
Indication under review: in combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults.
Cabozantinib offers an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors given in combination with a PD-1 inhibitor for this indication.
Medicines within this therapeutic class have been accepted under the end of life process for this indication.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice622KB (PDF)
- Medicine name:
- cabozantinib (Cabometyx)
- SMC ID:
in combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 11 October 2021